for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Endo International PLC

ENDP.OQ

Latest Trade

4.55USD

Change

-0.12(-2.57%)

Volume

1,114,116

Today's Range

4.51

 - 

4.77

52 Week Range

1.97

 - 

12.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.67
Open
4.77
Volume
1,114,116
3M AVG Volume
200.51
Today's High
4.77
Today's Low
4.51
52 Week High
12.91
52 Week Low
1.97
Shares Out (MIL)
226.78
Market Cap (MIL)
1,059.05
Forward P/E
2.11
Dividend (Yield %)
--

Next Event

Q4 2019 Endo International PLC Earnings Release

Latest Developments

More

Endo Announces FDA Acceptance Of Original Biologics License Application For Collagenase Clostridium Histolyticum To Treat Cellulite

Endo Says No "Direct News" From FDA About Application For Approval Of Cellulite Treatment

Endo Implements Says Chief Executive Officer Paul Campanelli To Retire

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Endo International PLC

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Industry

Biotechnology & Drugs

Contact Info

Minerva House, Simmonscourt Road

+353.1.2682000

http://www.endo.com

Executive Leadership

Paul V. Campanelli

Chairman of the Board, President, Chief Executive Officer

Blaise Coleman

Chief Financial Officer, Executive Vice President

Terrance John Coughlin

Chief Operating Officer, Executive Vice President

Patrick Barry

Executive Vice President and Chief Commercial Officer

Domenico Ciarico

Executive Vice President, Chief Commercial Officer - Sterile and Generics

Key Stats

3.07 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.0K

2017

3.5K

2018

2.9K

2019(E)

2.9K
EPS (USD)

2016

4.730

2017

3.840

2018

2.890

2019(E)

2.209
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.36
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
4.73
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-4.94
Return on Equity (TTM)
-4.05

Latest News

Latest News

Endo quarterly profit beat fueled by sterile injectables

Endo International Plc <ENDP.O> beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.

UPDATE 1-Endo quarterly profit beat fueled by sterile injectables

Endo International Plc beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.

Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case

Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Drugmaker Endo to pay $10 million to settle opioid lawsuit

Endo International Plc on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Endo gains on favorable FDA drug compounding decision

Endo International Plc said on Friday the U.S. health regulator has decided https://bit.ly/2XGrm1k not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version...

BRIEF-Paulson & Co Ups Share Stake In Discovery, Endo International

* PAULSON & CO INC CUTS SHARE STAKE IN VISTRA ENERGY CORP TO 3.7 MILLION SHARES FROM 10 MILLION SHARES - SEC FILING

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

Endo unit cleared of liability in first testosterone replacement trial

A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.

U.S. asks drug maker Endo to withdraw opioid amid abuse crisis

As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.

FDA asks Endo to withdraw Opana ER opioid, shares fall

The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company's shares down as much as 13 percent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up